Latest Chemomab Therapeutics News & Updates

See the latest news and media coverage for Chemomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Chemomab Therapeutics (Chemomab)

Clinical-stage biotechnology company developing fibro-inflammatory therapeutics

chemomab.com

Headquarters: Tel Aviv, Israel
Founded year: 2011
Company type: Public company
Number of employees: 20–50
Industry: Biotechnology & Medical Research

Last updated Yesterday

Latest news about Chemomab Therapeutics (Chemomab)

In short: Chemomab amended its Scipher merger, secured FDA Phase 3 alignment for nebokitug, and reported Q2 2026 results.

Company announcements

August 19 Chemomab

Chemomab reports Q2 2026 financial results and details a merger with Scipher

The company posted a net loss while advancing nebokitug for rheumatoid arthritis through the combined entity's precision medicine approach.

July 8 Chemomab

Chemomab announces merger agreement with Scipher Medicine to advance nebokitug

The combined company plans an AI-powered Phase 2 trial in rheumatoid arthritis using Scipher's platform.

May 14 Chemomab

Chemomab announced first quarter 2026 financial results

The company reported net loss of $1.8 million and provided updates on nebokitug clinical progress.

May 5 Chemomab

Chemomab announces nebokitug proteomic study results

Dr. Parvez Mantry presented dose-dependent reductions in inflammatory signatures at Digestive Disease Week. Data suggest benefits for PSC patients with IBD. Q1 2026 results release on May 14.

Media coverage

Yesterday TipRanks

Chemomab Restructures Into U.S. Parent Ahead of Merger With Scipher

Chemomab Therapeutics Ltd. is an Israel-based biopharmaceutical company that is restructuring its corporate framework through a U.S. domestication. Its operations and assets will be folded...

October 20 Defense World

Chemomab (NASDAQ: CMMB) lines up $50 million in merger-linked CVR payments - Defense World

What happened Chemomab Therapeutics Ltd. (NASDAQ: CMMB) filed a contingent value rights agreement on 2026-10-19 tied to its merger. The form gives holders two future...

September 30 Kalkine Media

Chemomab Therapeutics Updates Merger Agreement with Scipher Medicine Corporation

On September 30, 2026, Chemomab Therapeutics Ltd. submitted a Form 6-K, revealing that on September 23, 2026, the company executed Amendment No. 1 to its...

September 20 HCPLive

Nebokitug (CM-101) Gets FDA Runway for PSC Approval | HCPLive

Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in...

Never miss news about Chemomab

Track Chemomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Chemomab competitors & trending companies

Browse news for competitors to Chemomab and other trending companies.